Marina Biotech (MRNAD) to Updates on Nucleic Acid-Based Drug Discovery Platform

Marina Biotech, Inc. (Nasdaq: MRNAD), will provide an update on its nucleic acid-based drug discovery platform and 2012 goals at Biotech Showcase 2012 on Tuesday, January 10, 2012, at 5:30 p.m. Eastern Time (2:30 p.m. Pacific Time) at the Parc 55 Wyndham San Francisco in San Francisco.

In 2011, the Company established one of the industry's broadest nucleic acid-based drug discovery platforms:

• Two technologies partnered/licensed in two different oligonucleotide therapeutic areas: UsiRNA" in DiLA2" liposomal delivery via local administration and microRNA mimics in SMARTICLES liposomal delivery via systemic administration
  
• Two technologies in clinical development: shRNA delivered via a bacterial vector (tkRNAi") in the treatment of Familial Adenomatous Polyposis and a single-stranded DNAi via SMARTICLES in the treatment of solid tumors.

Marina Biotech's 2012 Goals include:

• Continued pursuit of strategic transactions including preclinical and clinical nucleic acid-based programs, additional delivery technologies and microRNA intellectual property
  
• Licensing of proprietary Unlocked Nucleobase Analog (UNA") and Conformationally Restricted Nucleotide (CRN") chemistries in the human, veterinary and agricultural fields as well as reagent and diagnostic areas
  
• Licensing of proprietary delivery technologies, including SMARTICLES, for the delivery of double and single-stranded nucleic acids
  
• Completing the Dose Escalating portion of the START-FAP Clinical Trial
  
• Establishing pharma collaboration(s) around multiple targets and therapeutic indications

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Boeing names Ryan Shedd as new SVP and controller
• Nu Skin EVP of global sales takes medical leave
• Home Depot expands executive roles, grants $500K in restricted stock